- Algernon Pharmaceuticals (AGN) has filed a pre-IND meeting request with the U.S. Food and Drug Administration
- Algernon is planning a phase 2 study of NP-120 (Ifenprodil) for the treatment of chronic cough
- Algernon could begin its phase 2 chronic cough study as early as Q2 of 2022
- Algernon is a clinical-stage pharmaceutical development company that investigates safe, approved drugs for new disease applications
- Algernon Pharmaceuticals Inc. (AGN) opened trading at C$0.08 per share
Algernon Pharmaceuticals (AGN) has filed a pre-IND meeting request with the U.S. Food and Drug Administration.
Algernon is planning a phase 2 study of NP-120 (Ifenprodil) for the treatment of chronic cough. Ifenprodil is an NMDA GluN2B subunit inhibitor and may represent a potential treatment for chronic cough.
Depending on the feedback from the U.S. FDA, the company could begin its phase 2 chronic cough study as early as Q2 of 2022.
“This submission to the U.S. FDA underscores our commitment to patients with refractory chronic cough,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals Inc.
“Many of these patients experience a significant negative impact on their quality of life, and there are currently no approved treatments.”
Algernon is a clinical-stage pharmaceutical development company that investigates safe, approved drugs for new disease applications.
Algernon Pharmaceuticals Inc. (AGN) opened trading at C$0.08 per share.
